The 237-patient randomized controlled trial led by Tang and Sherry demonstrates that circulating tumor DNA detection at baseline independently predicts progression and mortality in oligometastatic disease across six cancer subtypes, outperforming traditional lesion counting on CT/MRI. As a phase III-level RCT with balanced randomization to drug therapy alone versus combined stereotactic radiotherapy, the study provides high-quality evidence that ctDNA clearance after targeted radiation correlates with superior cancer control and survival. This addresses a critical gap missed in prior observational cohorts: real-time molecular monitoring can identify radioresistant clones not visible on scans. Synthesizing with the ORIOLE trial (JAMA Oncology, 2020; n=54, observational) and a 2023 JCO meta-analysis of 1,856 patients across solid tumors, patterns emerge showing ctDNA dynamics predict therapy resistance earlier than RECIST criteria by 2-4 months. Limitations include short follow-up and potential industry ties at MD Anderson, yet the scalable, non-invasive nature positions ctDNA as a monitoring tool that could reduce overtreatment while refining radiotherapy candidacy. Future integration with liquid biopsy panels may further personalize systemic therapy switches.